Aquestive Therapeutics, Inc. AQST Royalty obligations, net
Royalty obligations, net at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:RoyaltyObligationLiabilityNoncurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s royalty obligations, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s royalty obligations, net?
- Aquestive Therapeutics, Inc. (AQST) reported royalty obligations, net of $26.91M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s royalty obligations, net changed year-over-year?
- Aquestive Therapeutics, Inc.'s royalty obligations, net increased by 24.8% year-over-year, from $21.56M to $26.91M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s royalty obligations, net?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s royalty obligations, net has grown at a 32.6% compound annual growth rate (CAGR), from $14.76M to $25.94M.
- What does royalty obligations, net mean?
- This represents the long-term portion of royalty obligations owed to third parties, excluding amounts due within the next fiscal year. It reflects the company's multi-year commitment to share product revenue with external partners or licensors. Monitoring this provides insight into the long-term cost structure and the potential drag on future profitability associated with licensed technologies.